ENSC Key Statistics, Chart & Performance
The current stock price of ENSC is 1.425 USD. In the past month the price decreased by -31.16%. In the past year, price decreased by -74.64%.
ENSC Latest News, Press Relases and Analysis
ENSC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About ENSC
Company Profile
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Company Info
ENSYSCE BIOSCIENCES INC
7946 Ivanhoe Avenue, Suite 201
La Jolla CALIFORNIA US
CEO: Daniel B. Silvers
Employees: 7
Phone: 18582634196
ENSYSCE BIOSCIENCES INC / ENSC FAQ
Can you describe the business of ENSYSCE BIOSCIENCES INC?
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Can you provide the latest stock price for ENSYSCE BIOSCIENCES INC?
The current stock price of ENSC is 1.425 USD. The price increased by 0.35% in the last trading session.
What is the dividend status of ENSYSCE BIOSCIENCES INC?
ENSC does not pay a dividend.
What is the ChartMill technical and fundamental rating of ENSC stock?
ENSC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists ENSC stock?
ENSC stock is listed on the Nasdaq exchange.
What is the ownership structure of ENSYSCE BIOSCIENCES INC (ENSC)?
You can find the ownership structure of ENSYSCE BIOSCIENCES INC (ENSC) on the Ownership tab.
ENSC Technical Analysis
ENSC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ENSC. While ENSC seems to be doing ok healthwise, there are quite some concerns on its profitability.
ENSC Financial Highlights
Over the last trailing twelve months ENSC reported a non-GAAP Earnings per Share(EPS) of -6.37. The EPS increased by 79.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -345.1% | ||
| ROE | -911.79% | ||
| Debt/Equity | 0 |
ENSC Forecast & Estimates
7 analysts have analysed ENSC and the average price target is 26.75 USD. This implies a price increase of 1777.16% is expected in the next year compared to the current price of 1.425.
For the next year, analysts expect an EPS growth of 64.03% and a revenue growth -55.42% for ENSC